Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Seminars In Cancer Biology 2017, 52: 103-109. PMID: 29183778, PMCID: PMC5970946, DOI: 10.1016/j.semcancer.2017.11.019.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaCell lung carcinomaLung cancerWorld Health OrganizationLung carcinomaSignificant prognostic impactLung cancer patientsRecent large-scale genomic studiesSmall biopsy specimensDriver gene mutationsPrognostic impactCancer patientsBiopsy specimensTargeted therapyOncologic practiceAccurate subclassificationIHC biomarkersImmunohistochemical markersPatient careAccurate diagnosisImmunotherapyTherapyCancerSubclassificationCritical roleBiomarkers in the accurate subclassification of non-small-cell lung carcinoma for targeted therapy: issues and prospects
Osmani L, Li QK. Biomarkers in the accurate subclassification of non-small-cell lung carcinoma for targeted therapy: issues and prospects. Biomarkers In Medicine 2017, 11: 405-407. PMID: 28621614, DOI: 10.2217/bmm-2017-0059.Peer-Reviewed Original ResearchConceptsCell lung carcinomaLung carcinomaAccurate subclassificationCarcinomaTherapySubclassificationBiomarkers